RxDoctor Payments Data

Janice Jones, PA

Medical · Champaign, ILNPI 1114106002

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,861 of the $4,329 with a category attached, or 89.2%. 18 manufacturers reported payments, led by Johnson & Johnson at 24.3% of the total. 2025 is the largest year on record at $1,531, more than ten times the $87 reported in 2021.

$4,329in general payments, 2019–2025

Across 180 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AbbVie$697
  • Regeneron Healthcare Solutions, Inc.$528
  • Sanofi$331
  • Arcutis Biotherapeutics, Inc.$285
  • Amgen$205
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,86189%
  • Education$46811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,329 in reported general payments places this provider in the 85th percentile of 449 medical providers in Illinois.

See all medical providers in Illinois

Medicare billing

Part B allowed, 2024
$369,399
Medicare patients
1,660
Services billed
7,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab24$116,799
ZoryveRoflumilast34$30,284
Ketoconazole293$5,926
Betamethasone Dipropionate88$4,509
Ivermectin12$3,824
Azelaic Acid25$3,347
Calcipotriene41$2,887
Metronidazole42$2,286
Triamcinolone Acetonide198$2,251
Clobetasol Propionate45$1,355
Ciclopirox29$1,000
Doxycycline Hyclate64$761
Gentamicin Sulfate16$632
Clindamycin Phosphate12$388
ValacyclovirValacyclovir Hcl33$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arcutis Biotherapeutics, Inc.Zoryve$285$30,28434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 449 medical providers in Illinois.

Other medical in Champaign

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →